48 unknown, 24 recruiting, 16 not yet recruiting, 6 active not recruiting. 99 Phase 2, 9 Phase 1, 3 Phase 3.
Follow pyrotinib: new trials by email Literature Review of pyrotinib trials Research Report on pyrotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 26 | 2027-12-01 | 2026-09-22 |
| A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd Trastuzumab Deruxtecan (T-DXd), Pyrotinib - Breast Cancer | Phase 2 | Not yet recruiting | Fujian Medical University | 28 | 2026-10-10 | 2026-09-23 |
| Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer Trastuzumab Rezetecan, Pyrotinib, trastuzumab - HER2 + Breast Cancer, Advanced Breast Cancer | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 50 | 2026-09-30 | 2026-08-14 |
| Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 90 | 2026-07-01 | 2026-06-17 |
| Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer Dalpiciclib, Trastuzumab (Herceptin), Pertuzumab - Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 57 | 2026-06-01 | 2026-05-28 |
| SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study SHR-A1811, Pyrotinib, Capecitabine - Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 100 | 2026-03-31 | 2026-02-18 |
| Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer Trastuzumab Deruxtecan, Pertuzumab, Taxane Chemotherapy - HER2 + Breast Cancer | Phase 2 | Recruiting | Shanghai Jiao Tong University School of Medicine | 50 | 2026-02-02 | 2026-02-06 |
| Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer Nab paclitaxel, Carboplatin, Trastuzumab - HER2-positive Early Breast Cancer | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 200 | 2025-12-25 | 2026-01-21 |
| SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study SHR- A1811 - SHR-A1811, HER2-Postive Breast Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2025-12-20 | 2025-12-29 |
| Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study Trastuzumab rezetecan, Pyrotinib, Dalpiciclib - HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 288 | 2025-09-10 | 2025-09-18 |
| This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy. Patients will initially receive trastuzumab, pyrotinib, and albumin-bound paclitaxel. Those who do not achieve a radiological response after Cycle 2 will switch to SHR-A1811 (a HER2-targeted antibody, Patients will initially receive trastuzumab, pyrotinib, and nab-paclitaxel. Those who achieve a partial response (PR) or complete response (CR) after cycle 2 will continue on the same regimen. - HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 30 | 2025-09-01 | 2025-08-05 |
| SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer SHR-A1811 4.0mg/kg, Pyrotinib 240mg, SHR-A1811 4.8mg/kg - Metastatic Breast Cancer With HER2 Positive | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 84 | 2025-08-30 | 2025-08-20 |
| Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer Pyrotinib - Advanced Breast Cancer | Phase 2 | Recruiting | Wenjin Yin | 186 | 2025-08-28 | 2025-11-18 |
| A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors Sintilimab, Pyrotinib, Optional Chemotherapy - Advanced Digestive System Tumor | Phase 2 | Not yet recruiting | Tongji Hospital | 80 | 2025-08-15 | 2025-07-08 |
| Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer Pyrotinib, Capecitabine - HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-06-30 | 2025-06-13 |
| Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure entinostat, Pyrotinib, endocrine therapy - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 94 | 2025-06-23 | 2026-07-16 |
| Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis SHR-A1811, Bevacizumab, Pyrotinib - Breast Cancer Metastatic, Breast Cancer Brain Metastases | Phase 1 / Phase 2 | Recruiting | Fudan University | 74 | 2025-01-08 | 2025-02-06 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05) pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy - HER2-positive Breast Cancer, Neoadjuvant Therapy | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 33 | 2024-12-03 | 2025-02-18 |
| Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma Dalpiciclib + Pyrotinib - Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Peking University | 35 | 2024-11-01 | 2024-11-12 |
Showing 20 of 99. Sign in to see all of them.
Breast Neoplasms (52) · Carcinoma, Non-Small-Cell Lung (6) · Brain Neoplasms (4) · Breast Diseases (3) · Esophageal Squamous Cell Carcinoma (2) · Triple Negative Breast Neoplasms (2) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Digestive System Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Pathologic Complete Response (1) · Salivary Gland Neoplasms (1) · Stomach Neoplasms (1)
Fudan University (12) · Chinese Academy of Medical Sciences (6) · Henan Cancer Hospital (6) · Sun Yat-sen University (6) · Tianjin Medical University Cancer Institute and Hospital (6) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5) · The First Affiliated Hospital with Nanjing Medical University (5) · Shanghai Jiao Tong University School of Medicine (4) · Jiangsu HengRui Medicine Co., Ltd. (3) · Peking Union Medical College Hospital (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Fujian Medical University (2) · Hebei Medical University Fourth Hospital (2) · Peking Union Medical College (2)
China (78)
Binghe Xu (2) · Min Yan (2) · Xuexin He, MD (2) · Biyun Wang, Chief physician (1) · Caicun Zhou, MD,PhD (1) · Caigang Liu, MD (1) · Chen Xi, PhD (1) · Chunling Jiang (1) · Dingzhi Huang, Doctor (1) · Erwei Song, MD.,Phd. (1) · Fei Ma (1) · Fei Xu, MD (1) · Feilin Cao, Master (1) · Gong Chang, doctor (1)
PMID 37296463, PMID 39024777, PMID 28115222, PMID 28498781, PMID 30596880, PMID 31430226, PMID 32614698, PMID 32660609, PMID 32719455, PMID 33328035, PMID 33570247, PMID 34083331, PMID 35085506, PMID 35105939, PMID 35287613, PMID 35321427, PMID 35713517, PMID 35941028, PMID 36135045, PMID 37805496, PMID 38175627, PMID 38290515, PMID 38328709, PMID 38362377, PMID 38469548, PMID 38871705, PMID 39380967, PMID 39425028, PMID 39648226, PMID 40178527, PMID 40743286